Search Results

You are looking at 101 - 110 of 290 items for :

  • "neutropenia" x
Clear All
Full access

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III and Arti Hurria

concurrent chemotherapy and radiation. They found that although acute toxicities (esophagitis and neutropenia) were higher in older patients, no differences were seen in long-term toxicity or overall survival based on age. In a similar analysis, Schild et al

Full access

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Vishala T. Neppalli, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Mary A. Dwyer and Hema Sundar

was also active in patients with Richter's transformation (n=30), resulting in an ORR of 43% (27% CR), and the 1-year OS rate was 28%. 30 However, it was associated with significant toxicity (grade 3 neutropenia was the most common hematologic

Full access

Andrew D. Zelenetz

otherwise specified, angioimmunoblastic T-cell lymphoma, and sALCL (ALK1-negative). The most common treatment-related toxicities were nausea, vomiting, diarrhea, infection, asthenia, thrombocytopenia, and neutropenia. Cardiac toxicity was minimal (6

Full access

Presenter : Eunice S. Wang

secondary AML.” One clinical caveat is that rates of myelosuppression and febrile neutropenia with infections were significantly higher for the combination regimen than for azacitidine alone, with many patients requiring close monitoring and frequent

Full access

Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary A. Dwyer and Maoko Naganuma

neutropenia (70%), thrombocytopenia (45%), anemia (18%), and febrile neutropenia (15%). 17 Lenalidomide was administered using different dosing schedules in these earlier studies. In one study, patients initially received lenalidomide at the 25-mg-daily dose

Full access

Stephen Harnicar

monitor for and manage toxicities associated with imatinib. A CBC count should be performed weekly for the first month, every 2 weeks for the second month, and periodically thereafter (e.g., every 2-3 months). Hematologic toxicities, including neutropenia

Full access

Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova-Rusher, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer and Deborah A. Freedman-Cass

itself (eg, hypogammaglobulinemia in chronic lymphocytic leukemia or multiple myeloma). 54 – 58 In particular, chemotherapy can cause neutropenia, a major risk factor for the development of infections. 59 The frequency and severity of infection are

Full access

Armin Rashidi and Nancy L. Bartlett

20 months, and the median PFS for all patients was 5.6 months (21.7 months for those who achieved a CR). The most common adverse event was peripheral sensory neuropathy (42%) and the most common grade 3 to 4 adverse event was neutropenia (20%). In

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar and Leonard B. Saltz

) The most common grade 1/2 toxicities with FOLFOX were fatigue (58%), nausea (32%), and neutropenia (25%). The most common grade 3 toxicities were diarrhea (4%), fatigue (1%), nausea (1%), and neutropenia (1%). These were managed with dose reductions

Full access

Saurabh Rajguru and Brad S. Kahl

PFS was just 4 months, but the median response duration was 16.6 months, suggesting substantial clinical benefit in patients responding to treatment. The most common grade 3/4 AEs were neutropenia (43%) and thrombocytopenia (27%), with 34% and 31% of